Recently, the API industry has been dynamic, including Xinhua Pharmaceutical, Xintiandi Pharmaceutical and other pharmaceutical companies have expressed plans
to build production bases in order to break through development.
However, recently, a pharmaceutical company has "retrograde" and intends to sell some API production workshop assets, which has attracted attention
in the industry.
ST Guodan announced on November 21 that the company intends to sell part of the API production workshop assets it holds to Jiangsu Yingke Biopharmaceutical Co.
, Ltd.
The sale price refers to the appraisal value of 4,004,600 yuan stated in the "Appraisal Report" issued by Wanlong Asset Appraisal Co.
, Ltd
.
, and is determined to be 4 million yuan after voluntary and equal consultation between the two parties.
The transaction consideration is paid
in cash.
For this sale, the Company believes that the completion of the sale is conducive to optimizing the asset structure
.
In the long term, reducing fixed costs and finance expenses has a positive impact
on the company's future financial position.
According to the data, Jiangsu Yingke Biopharmaceutical Co.
, Ltd.
, which participated in the transaction, is mainly committed to the research and development of parenteral nutrition emulsions, drug delivery fat emulsion series, anesthesia series products, the company's production workshops built in strict accordance with the new GMP standards include: lentinan API workshop, lyophilized powder injection workshop, small volume injection workshop, large volume injection workshop (multi-layer co-extrusion film infusion bag), soft capsule preparation workshop, traditional Chinese medicine extraction workshop, etc
.
The main business of Guotan Biotech is the production and sales of chemicals and injections, the main products and services are: raw materials, tablets, hard capsules, granules, small-volume injection production, drug retail, drug wholesale, technology research and development of drugs and biological products, technology transfer, drug information consultation (excluding diagnosis and treatment), self-operated and agent import and export business of various commodities and technologies (except commodities and technologies restricted or prohibited by the state).
According to the 2021 annual report, the company achieved operating income of 1.
3941 million yuan during the reporting period, a year-on-year increase of 30.
33%; The net profit attributable to shareholders of the listed company was -10.
7804 million yuan, which was less
than the loss in the same period of the previous year.
According to the company's 2022 half-year report, in the first half of 2022, the operating income was 541,500 yuan, a year-on-year decrease of 16.
17%, and the net profit attributable to the shareholders of the listed company was -4.
3034 million yuan, a year-on-year loss reduction
.
At the same time, the company's sales expenses and R&D expenses in the first half of this year have decreased, mainly because the company has reduced publicity and promotion expenses in order to save sales costs, and streamlined R&D projects to reduce R&D risks
.
The company stated in the half-year report that the company focuses on the research and development of special dosage forms and the innovative research and development of antipsychotic drugs as the company's development baseline, while taking into account the variety development strategy with market prospects and the development of children's drugs
.
Through technology and product innovation, market and marketing management, to achieve the company's development strategy
.
In the next 10 years, the company strives to become one of
the leading enterprises in the research and development and production of antipsychotropic drugs and children's drugs.
From the perspective of product pipeline, the products that the company has obtained production approval include baloxacin capsules, cimetidine capsules, ethambutol hydrochloride tablets, ambroxol hydrochloride injection and fasudil hydrochloride injection; After the reporting period, the research and development of special dosage forms and the generic innovative research and development of antipsychotic drugs will be used as the company's development baseline, such as quinthiapine fumarate sustained-release tablets, atorvastatin calcium tablets, etc.
developed by the company; At the same time, the company takes into account the varieties with market sales prospects and the development of children's drugs as an auxiliary variety development strategy, such as inhaled ambroxol solution
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
![3-fluorodibenzo[b,d]furan](https://file.echemi.com/fileManage/upload/category/ac71ac0d-8ef6-11ec-89e5-fa163ed06441.png)
![2,6-Dibromo-4,4-bis(2-ethylhexyl)-4H-silolo[3,2-b:4,5-b']dithiophene](https://file.echemi.com/fileManage/upload/canonicalSmiles/20220811/27c7aefc886740ceb896628aa7d359ad.png)
